In a blog post for BIOtechNOW, John Sterling, editor-in-chief of Genetic Engineering & Biotechnology News, shares his top ten “can’t miss” sessions at the 2013 BIO International Convention in Chicago this April.
DOUBLE FEATURE — Finding second chances on Capitol Hill. Congress switches gears on STEM visas for life scientists and a revived MODDERN Cures Act aims to stimulate "dormant" drugs and the diagnostics landscape.
Join us at the 2013 BIO International Convention for a conversation with an awe-inspiring group of young, rising stars in biotech and learn how they are changing the way science, innovation and healthcare are progressing.
Read the press release
Learn more about the Keynote Luncheons
How can countries and regions boost the biotech industry within their borders? Working with several member companies, BIO developed a Global Policy Platform to serve as a roadmap for policymakers seeking to create an environment for the biotech industry to grow and prosper.
At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet. We have used the biological processes of microorganisms for more than 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.
Congress created the 340B program in 1992 to help uninsured indigent patients gain better access...
|
Biotechnology can help society solve old problems in new ways. Through the science of using...
|
At a time when the global economy struggles to recover from a severe recession and uncertainty...
|
BIO recently announced its selection of Congressman Richard Neal (D-MA) as Legislator of the Year for 2012-2013 during the 2013 BIO Legislative Day Fly-In.
"Congressman Neal's sponsorship, along with Congressman Gerlach, of the High Technology Small Business Research Incentives Act would help emerging companies find new sources of investment. Furthermore, the Congressman's joint work on legislation to address the Vaccine Excise Tax merits particular commendation," said BIO President and CEO Jim Greenwood.